Amantadine dosage in treatment of Parkinson's disease.

Suppr

超能文献

作者信息

Parkes J D, Zilkha K J, Marsden P, Baxter R C, Knill-Jones R P

出版信息

Lancet. 1970 May 30;1(7657):1130-3. doi: 10.1016/s0140-6736(70)91211-0.

DOI:10.1016/s0140-6736(70)91211-0

PMID:4192093

Abstract

摘要

相似文献

Amantadine dosage in treatment of Parkinson's disease.

Lancet. 1970 May 30;1(7657):1130-3. doi: 10.1016/s0140-6736(70)91211-0.

[Amantadine in the treatment of Parkinson's disease].

Fracastoro. 1970 Nov-Dec;63(6):869-81.

Amantadine hydrochloride in the treatment of Parkinson's disease.盐酸金刚烷胺治疗帕金森病。

Med J Aust. 1970 Oct 3;2(14):634-7. doi: 10.5694/j.1326-5377.1970.tb50241.x.

Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease.

Trans Am Neurol Assoc. 1969;94:85-90.

Amantadine in the treatment of Parkinson's disease.金刚烷胺治疗帕金森病

JAMA. 1969 May 19;208(7):1168-70.

[Clinical trial of the therapeutic effect of Amantadine-HCL in Parkinson's Disease].

Schweiz Med Wochenschr. 1972 Apr 22;102(16):583-6.

Amantadine-HCl in the treatment of Parkinson's disease: a controlled trial.盐酸金刚烷胺治疗帕金森病：一项对照试验。

J Clin Pharmacol New Drugs. 1972 Jul;12(7):274-9. doi: 10.1002/j.1552-4604.1972.tb00055.x.

[Amantadine in the treatment of Parkinson's disease].[金刚烷胺在帕金森病治疗中的应用]

Rev Med Liege. 1972 Dec 1;27(23):835-7.

Amantadine therapy in parkinsonism.帕金森病的金刚烷胺治疗。

Acta Neurol Scand. 1972;48(1):1-18. doi: 10.1111/j.1600-0404.1972.tb07524.x.

Comparison of amantadine, placebo, and levodopa in Parkinson's disease.金刚烷胺、安慰剂和左旋多巴在帕金森病中的比较。

Neurology. 1974 Aug;24(8):715-20. doi: 10.1212/wnl.24.8.715.

引用本文的文献

Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies.健康志愿者每日一次服用金刚烷胺缓释片的生物利用度和药代动力学：三项随机、交叉、开放标签的1期研究结果

Neurol Ther. 2019 Dec;8(2):449-460. doi: 10.1007/s40120-019-0144-1. Epub 2019 Aug 1.

NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.NMDA 拮抗剂治疗帕金森病的非运动症状。

Transl Psychiatry. 2018 Jun 15;8(1):117. doi: 10.1038/s41398-018-0162-2.

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.异动症帕金森病患者从速释金刚烷胺转换为开放标签的ADS-5102。

Mov Disord Clin Pract. 2018 Mar-Apr;5(2):183-190. doi: 10.1002/mdc3.12595. Epub 2018 Feb 23.

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.ADDS-5102（金刚烷胺）缓释胶囊每日睡前一次给药治疗运动障碍的药代动力学。

Clin Pharmacokinet. 2019 Jan;58(1):77-88. doi: 10.1007/s40262-018-0663-4.

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).ADDS-5102（金刚烷胺）控释胶囊治疗帕金森病左旋多巴诱导运动障碍的随机、安慰剂对照试验（EASE LID 3）。

Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.用于帕金森病左旋多巴诱导的异动症的ADS-5102（金刚烷胺）缓释胶囊（EASE LID 2研究）：一项开放标签安全性研究的中期结果。

J Parkinsons Dis. 2017;7(3):511-522. doi: 10.3233/JPD-171134.

Parkinsonism-physiology and pharmacology.帕金森症——生理学与药理学

Br Med J. 1971 Sep 18;3(5776):693-7. doi: 10.1136/bmj.3.5776.693.

Amantadine in Parkinson's disease.金刚烷胺在帕金森病中的应用。

Cochrane Database Syst Rev. 2003;2003(1):CD003468. doi: 10.1002/14651858.CD003468.

Economic and health-related quality of life considerations of new therapies in Parkinson's disease.帕金森病新疗法的经济及与健康相关的生活质量考量

Pharmacoeconomics. 2001;19(7):729-52. doi: 10.2165/00019053-200119070-00003.

Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.抗帕金森病药物的神经精神不良反应。特征、评估与治疗。

Drugs Aging. 1997 May;10(5):367-83. doi: 10.2165/00002512-199710050-00005.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验